54696-64-9

Upstream product

• 5470-18-8 2-Chloro-3-nitropyridine 
• 108-44-1 1-amino-3-methylbenzene 

Downstream Products

• 1399050-08-8 C₁₄H₁₄N₃⁽¹⁺⁾*Cl^(1-) 
• 1399050-07-7 N₃-methyl-N₂-(m-tolyl)pyridine-2,3-diamine 
• 1393181-19-5 N-{(1S)-1-[3-(3-methylphenyl)-3H-imidazo[4,5-b]pyridin-2-yl]ethyl}-9H-purin-6-amine 
• 1393177-07-5 (S)-1-(3-m-tolyl-3H-imidazo[4,5-b]pyridin-2-yl)ethylamine 
• 1393177-06-4 [(S)-1-(3-m-tolyl-3H-imidazo[4,5-b]pyridin-2-yl)ethyl]carbamic acid tert-butyl ester 
• 1393177-05-3 [(S)-1-(2-m-tolylaminopyridin-3-ylcarbamoyl)ethyl]carbamic acid tert-butyl ester 
• 176032-17-0 3-amino-2-[(m-tolyl)amino]pyridine 

Relevant academic research and scientific papers

PYRIDYL CARBENE PHOSPHORESCENT EMITTERS

Organometallic compounds comprising an imidazole carbene ligand having a N- containing ring fused to the imidazole ring are provided. In particular, the N-containing ring fused to the imidazole ring may contain one nitrogen atom or more than one nitrogen

HETEROCYCLIC COMPOUNDS AND METHODS OF USE

Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

PYRIDYL CARBENE PHOSPHORESCENT EMITTERS

Organometallic compounds comprising an imidazole carbene ligand having a N-containing ring fused to the imidazole ring are provided. In particular, the N-containing ring fused to the imidazole ring may contain one nitrogen atom or more than one nitrogen a